-
1
The study reviewed records of 650 patients with type 2 diabetes.
-
2
Deprescribing occurred in 6% of cases.
-
3
Mean body mass index decreased by 2 kg/m².
-
4
Glucose levels decreased by 25%; hemoglobin A1c by 13%.
-
5
Most common changes were metformin dose reduction and discontinuation.
-
6
Lifestyle changes documented in 51% of cases, with dietary changes prevalent.
-
7
No serious adverse events were reported; few unrelated adverse events noted.
-
8
The study highlights safety and efficacy of deprescribing in routine care.
Original Source(s)
Related Content
Was the GLP-1 Problem Always Cost?
A JAMA Viewpoint argues the BALANCE model targets the leading cause of discontinuation.
by Kerri Miller
April 3, 2026
-
2 min
FDA Approves Lilly’s Foundayo Oral GLP-1 Pill
The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.
April 1, 2026
-
2 min
PFAS Exposure Linked to Faster Epigenetic Aging
Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64
April 1, 2026
-
2 min
